Loading
Latest filing published 11 Sept 2024 for Foghorn Therapeutics Inc., €172k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Steven F. Bellon in Foghorn Therapeutics Inc., where the filings describe the role as senior executive. In total, 3 filings cover trades dated from 25 May 2022 to 9 September 2024.
Every open-market trade on record is a sale: 1 sale worth €172k. The rest of the record consists of 2 option exercises. In 2024 alone, the filings show no purchases and 1 sale.
The latest filing, published on 11 September 2024, reports an open-market sale of €172k in Foghorn Therapeutics Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations